Monoclonal antibodies in treatment of multiple sclerosis

P. S. Rommer, A. Dudesek, O. Stüve, U. K. Zettl

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Summary: Monoclonal antibodies (mAbs) are used as therapeutics in a number of disciplines in medicine, such as oncology, rheumatology, gastroenterology, dermatology and transplant rejection prevention. Since the introduction and reintroduction of the anti-alpha4-integrin mAb natalizumab in 2004 and 2006, mAbs have gained relevance in the treatment of multiple sclerosis (MS). At present, numerous mAbs have been tested in clinical trials in relapsing-remitting MS, and in progressive forms of MS. One of the agents that might soon be approved for very active forms of relapsing-remitting MS is alemtuzumab, a humanized mAb against CD52. This review provides insights into clinical studies with the mAbs natalizumab, alemtuzumab, daclizumab, rituximab, ocrelizumab and ofatumumab.

Original languageEnglish (US)
Pages (from-to)373-384
Number of pages12
JournalClinical and Experimental Immunology
Issue number3
StatePublished - Mar 2014


  • Alemtuzumab
  • Daclizumab
  • Multiple sclerosis
  • Natalizumab
  • Rituximab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Monoclonal antibodies in treatment of multiple sclerosis'. Together they form a unique fingerprint.

Cite this